Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 289

1.
2.

Summary of AHRQ's comparative effectiveness review of drug therapy for rheumatoid arthritis (RA) in adults--an update.

Singh JA, Cameron DR.

J Manag Care Pharm. 2012 May;18(4 Supp C):S1-18. Review.

PMID:
22656072
3.

Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis.

Kemper AR, Van Mater HA, Coeytaux RR, Williams JW Jr, Sanders GD.

BMC Pediatr. 2012 Mar 15;12:29. doi: 10.1186/1471-2431-12-29. Review.

4.

Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA) [Internet].

Kemper AR, Coeytaux R, Sanders GD, Van Mater H, Williams JW, Gray RN, Irvine RJ, Kendrick A.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2011 Sep.

5.

The comparative safety and effectiveness of TNF-alpha antagonists [corrected].

Solomon DH.

J Manag Care Pharm. 2007 Jan;13(1 Suppl):S7-18. Review. Erratum in: J Manag Care Pharm. 2007 Apr;13(3):292.

PMID:
17378700
6.

The humanistic and economic burden of juvenile idiopathic arthritis in the era of biologic medication.

Gidman W, Meacock R, Symmons D.

Curr Rheumatol Rep. 2015 May;17(5):31. doi: 10.1007/s11926-015-0508-1. Review.

PMID:
25874347
7.

Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis.

Donahue KE, Gartlehner G, Jonas DE, Lux LJ, Thieda P, Jonas BL, Hansen RA, Morgan LC, Lohr KN.

Ann Intern Med. 2008 Jan 15;148(2):124-34. Review.

PMID:
18025440
8.

Biologic agents in rheumatoid arthritis: an update for managed care professionals.

Agarwal SK.

J Manag Care Pharm. 2011 Nov-Dec;17(9 Suppl B):S14-8. Review.

9.

The role of synthetic drugs in the biologic era: therapeutic strategies for treating juvenile idiopathic arthritis.

Hügle B, Horneff G.

Expert Opin Pharmacother. 2016;17(5):703-14. doi: 10.1517/14656566.2016.1133592. Review.

PMID:
26678914
10.

Advanced therapy for juvenile arthritis.

Murray KJ, Lovell DJ.

Best Pract Res Clin Rheumatol. 2002 Jul;16(3):361-78. Review.

PMID:
12387805
11.

The use of biologic response modifiers in polyarticular-course juvenile idiopathic arthritis: a systematic review.

Ungar WJ, Costa V, Burnett HF, Feldman BM, Laxer RM.

Semin Arthritis Rheum. 2013 Jun;42(6):597-618. doi: 10.1016/j.semarthrit.2012.10.006. Review.

PMID:
23337074
12.

Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. Review.

13.

Clinical utility of etanercept in the treatment of arthritides in children and adolescents.

Dore RK.

Adolesc Health Med Ther. 2014 Mar 26;5:35-48. doi: 10.2147/AHMT.S38909. Review.

14.

Abatacept in the treatment of polyarticular JIA: development, clinical utility, and place in therapy.

Goldzweig O, Hashkes PJ.

Drug Des Devel Ther. 2011 Jan 26;5:61-70. doi: 10.2147/DDDT.S16489. Review.

15.

Judicious use of biologicals in juvenile idiopathic arthritis.

Zhao Y, Wallace C.

Curr Rheumatol Rep. 2014 Nov;16(11):454. doi: 10.1007/s11926-014-0454-3. Review.

PMID:
25218736
16.

Juvenile idiopathic arthritis: new insights into classification, measures of outcome, and pharmacotherapy.

Beresford MW.

Paediatr Drugs. 2011 Jun 1;13(3):161-73. doi: 10.2165/11588140-000000000-00000. Review.

PMID:
21500870
17.

Tumor necrosis factor inhibitors in the management of juvenile idiopathic arthritis: an evidence-based review.

Shenoi S, Wallace CA.

Paediatr Drugs. 2010 Dec 1;12(6):367-77. doi: 10.2165/11532610-000000000-00000. Review.

PMID:
21028916
18.

Treatment of juvenile idiopathic arthritis: a revolution in care.

Stoll ML, Cron RQ.

Pediatr Rheumatol Online J. 2014 Apr 23;12:13. doi: 10.1186/1546-0096-12-13. Review.

19.

Drug Therapy for Psoriatic Arthritis in Adults: Update of a 2007 Report [Internet].

Donahue KE, Jonas D, Hansen RA, Roubey R, Jonas B, Lux LJ, Gartlehner G, Harden E, Yuen A, Thieda P, Morgan LC, Crotty K, Van Noord M.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Apr.

20.

Management of Children with Juvenile Idiopathic Arthritis.

Viswanathan V, Murray KJ.

Indian J Pediatr. 2016 Jan;83(1):63-70. doi: 10.1007/s12098-015-1966-1. Review.

PMID:
26639461

Supplemental Content

Support Center